Boehringer Ingelheim on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals use contract pharmacies.

Boehringer Ingelheim Halts 340B Pricing on Contract Pharmacy Drugs

Boehringer Ingelheim (BI) on Sunday became the seventh drug manufacturer to deny 340B pricing on its products when hospitals contract with pharmacies to dispense the medicines, hospitals reported yesterday.

 

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content